




FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER
PARTNER
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3184
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

April 17, 2003

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: BOX DD, Commissioner for Patents, Washington, DC 20231, on the date below:	
April 17, 2003	
Date	Steven L. Highlander

BOX DD

Commissioner for Patents
Washington, DC 20231

RE: *U.S. Patent Application No. 09/989,695 entitled "LIPOSOMAL IMEXON" – Gabriel Lopez-Berestein et al.*
Our reference: UTSC:648US
Client reference: MDA00-024

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references A2-A3, B7, C15-C16.

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSC:648US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642

SLH/cmb
Encl.: as noted
25280053.1



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Gabriel Lopez-Berestein *et al.*

Serial No.: 09/989,695

Filed: November 20, 2001

For: LIPOSOMAL IMEXON


Group Art Unit: 1615

Examiner: Unknown

Atty. Dkt. No.: UTSC:648US

APR 24 2003

RECEIVED 1600/2003

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Box DD, Commissioner for Patents, Washington, DC 20231, on the date below:	
April 17, 2003	
Date	Steven L. Highlander

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

BOX DD

Commissioner for Patents
Washington, D.C. 20231

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSC:648US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: April 17, 2003

Form PTO-1449 (modified)

Atty. Docket No.

UTSC:648US

Serial No.

09/989,695

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Gabriel Lopez-Berestein *et al.*

Filing Date:

November 20, 2001

Group:

1615

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A2	4,321,194	3/23/82	Bosies <i>et al.</i>	260	239	7/23/79
	A3	4,397,848	8/9/83	Bosies <i>et al.</i>	424	244	2/20/81

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B7	DE 3844655	5/17/90	Germany			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C15	Dorr <i>et al.</i> , "Preclinical pharmacokinetics and antitumor activity of imexon," <i>Investigational New Drugs</i> , 13:113-116, 1995.
	C16	Hersh <i>et al.</i> , "Suppression of human lymphoma development in the severe combined immune-deficient mouse by imexon therapy," <i>J. of Immunotherapy</i> , 13:77-83, 1993.

25280044.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)